Bind Therapeutics, Inc.

Pfizer Corporation

Bind Biosciences, Inc.

Astrazeneca Ab

Merck Sharp + Dohme Corp.

Greg Troiano

James I Wright

Stephen E Zale

Mir Mukkaram Ali

Jeff Hrkach

Young-Ho Song

Christina Van Geen Hoven

Michael Figa

Abhimanyu Sabnis

Hong Wang

Maria Figueiredo

David Dewitt

Eyoung Shin

Erick Peeke

Young Ho Song

Jennifer A Lafontaine

Marianne Bernice Ashford

Jason Auer

Tarikh Christopher Campbell

Shubha Bagrodia

James Martin Nolan, Iii

Zach Lovatt

Michael H Lam

Caroline McGregor

Yong-ho Song

Tina Van Geen Hoven

James Martin Iii Nolan

Tina Van Geen Uoven

Susan Low

Young Ho Sung

Caroline Mcgregor

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.

Therapeutic nanoparticles comprising a protonatable nitrogen therapeutic agent and methods of making and using same

Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.

Therapeutic polymeric nanoparticles and methods of making and using same

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same

Described herein are polymeric nanoparticles that comprise 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]-triazolo-[3,4-fJ[1,6]-naphthyridin-3-one (Compound A), or a pharmaceutically acceptable salt thereof, and methods of making and using such nanoparticles. The nanoparticle comprises about 50 to about 99.8 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic acid-co-glycolic acid)-poly(ethylene)glycol copolymer, wherein the total amount of poly(ethylene)glycol in the nanoparticle is about 10 to about 30 weight percent poly(ethylene)glycol and about 0.2 to about 30 weight percent of Compound A.

Polymeric nanoparticles and methods of making and using same

The present disclosure generally relates to a process for preparing therapeutic nanoparticles, where the process includes combining a therapeutic agent with an organic acid. The therapeutic nanoparticles may have, for example, improved drug loading and/or drug release properties.

Process for preparing therapeutic nanoparticles

The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.

Drug loaded polymeric nanoparticles and methods of making and using same

The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Stable formulations for lyophilizing therapeutic particles

The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.

Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.

Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same

The present disclosure generally relates to lyophilized pharmaceutical compositions comprising a sugar, a cyclodextrin, and polymeric nanoparticles comprising a copolymer and a therapeutic agent which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Growing community of inventors

Pembroke, MA, United States of America

Greg Troiano